SYRE
8:00 AM
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the
Trial Results • Phase 2spyre.com